AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32115853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 35447283 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy followed by pre-operative chemotherapy (EXP)
Number of subjects: 574
Study 35447283 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy and optional post-operative chemotherapy (STD)
Number of subjects: 574
Study 35447283 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy and optional post-operative chemotherapy (STD+)
Number of subjects: 574
Study 35447283 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy without post-operative chemotherapy (STD-)
Number of subjects: 574
Study 33754435 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser
Number of subjects: 240
Study 33754435 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodentine®
Number of subjects: 240
Study 33754435 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric sulphate
Number of subjects: 240
Study 33754435 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Number of subjects: 240
Study 33754435 — intervention group
Group type: EXPERIMENTAL
Intervention: Atmospheric pressure cold plasma (APCP)
Number of subjects: 240
Study 34221478 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental knowledge regarding antibiotic use for URTIs
Number of subjects: 384
Study 34221478 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental beliefs about antibiotic effectiveness
Number of subjects: 384
Study 34221478 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental practices regarding antibiotic prescriptions
Number of subjects: 384
Study 34221478 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental attitudes towards physician prescribing
Number of subjects: 384
Study 32007541 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy after negative FIT results
Number of subjects: 96804
Study 33807296 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Number of subjects: 68
Study 33807296 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 68
Study 32396966 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiotaping (KT) with 10% tape tension
Number of subjects: 66
Study 32396966 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 66
Study 32396966 — intervention group
Group type: COMPARATOR
Intervention: Sham (no tape tension)
Number of subjects: 66
Study 36336697 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported physical activity
Number of subjects: 430
Study 36336697 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometer-measured physical activity
Number of subjects: 430
Study 36336697 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported data
Number of subjects: 430
Study 36336697 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report and accelerometry data
Number of subjects: 430
Study 32996559 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional, inflammatory, hormonal and muscle biomarkers
Number of subjects: 193
Study 32996559 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamate, hydroxyproline, tau-methylhistidine levels, and sex
Number of subjects: 193
Study 32996559 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-adjusted model including sex and 3 amino-acids
Number of subjects: 193
Study 32996559 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-adjusted model including sex, hydroxyproline, and Charlson Comorbidity Index
Number of subjects: 193
Study 35172876 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile water injections (6 injections of sterile water, 0.1-0.3 ml per injection)
Number of subjects: 154
Study 35172876 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride 0.9% solution (placebo, 0.1-0.3 ml per injection)
Number of subjects: 154
Study 35172876 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile water injections
Number of subjects: 154
Study 34500174 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 hours of auditory-based targeted cognitive training (TCT) + treatment-as-usual (TAU)
Number of subjects: 42
Study 34500174 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 42
Study 35020047 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) + episodic future thinking (EFT)
Number of subjects: 72
Study 35020047 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) + episodic future thinking (EFT) + contingency management
Number of subjects: 72
Study 32044190 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer coaching intervention
Number of subjects: 55
Study 34159869 — intervention group
Group type: EXPERIMENTAL
Intervention: Storytelling structures
Number of subjects: 0
Study 34159869 — intervention group
Group type: EXPERIMENTAL
Intervention: Magic structures
Number of subjects: 0
Study 34159869 — intervention group
Group type: EXPERIMENTAL
Intervention: Agent-based computational model
Number of subjects: 0
Study 34159869 — intervention group
Group type: COMPARATOR
Intervention: Double-blind control studies
Number of subjects: 0
Study 33585998 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 26
Study 33585998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 32668087 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure (PE) plus placebo
Number of subjects: 64
Study 32668087 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline plus enhanced medication management
Number of subjects: 64
Study 32668087 — intervention group
Group type: EXPERIMENTAL
Intervention: PE plus sertraline
Number of subjects: 64
Study 32668087 — intervention group
Group type: COMPARATOR
Intervention: Control group (trauma-exposed veterans without PTSD)
Number of subjects: 64
Study 32820619 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose apararenone (3.75-640 mg)
Number of subjects: 223
Study 32820619 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose apararenone (10-40 mg/day on days 1-14, 320 mg loading dose on day 1 + 10 mg/day on days 2-14, or 40-320 mg loading dose on day 1 + 2.5-20 mg/day on days 2-14)
Number of subjects: 223
Study 32820619 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose apararenone (5-320 mg)
Number of subjects: 223
Study 32820619 — intervention group
Group type: COMPARATOR
Intervention: Single-dose apararenone (160 or 640 mg)
Number of subjects: 223
Study 32820619 — intervention group
Group type: COMPARATOR
Intervention: Eplerenone (200 mg)
Number of subjects: 223
Study 32820619 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone challenge
Number of subjects: 223
Study 32600078 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial damage group
Number of subjects: 82
Study 32600078 — intervention group
Group type: COMPARATOR
Intervention: Non-myocardial damage group
Number of subjects: 82
Study 32600078 — intervention group
Group type: EXPERIMENTAL
Intervention: Age >70 years old
Number of subjects: 82
Study 32600078 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP >100 mg/L
Number of subjects: 82
Study 32600078 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate dehydrogenase >300 U/L
Number of subjects: 82
Study 32600078 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactic acid >3 mmol/L
Number of subjects: 82
Study 34404473 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-alcohol
Number of subjects: 311
Study 34404473 — intervention group
Group type: COMPARATOR
Intervention: Povidone-iodine
Number of subjects: 311
Study 32896753 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation
Number of subjects: 32
Study 32896753 — intervention group
Group type: COMPARATOR
Intervention: Standard breast cancer treatment
Number of subjects: 32
Study 36404704 — intervention group
Group type: EXPERIMENTAL
Intervention: Human threat agency
Number of subjects: 449
Study 36404704 — intervention group
Group type: EXPERIMENTAL
Intervention: Human temporal agency
Number of subjects: 449
Study 36404704 — intervention group
Group type: COMPARATOR
Intervention: Bacteria threat agency
Number of subjects: 449
Study 36404704 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic resistance condition
Number of subjects: 449
Study 34370941 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment program conducted across 6 sessions
Number of subjects: 80
Study 34244715 — intervention group
Group type: EXPERIMENTAL
Intervention: Incisional negative-pressure wound therapy (iNPWT)
Number of subjects: 85
Study 34244715 — intervention group
Group type: COMPARATOR
Intervention: Standard dressing with suction drain
Number of subjects: 85
Study 34371907 — intervention group
Group type: COMPARATOR
Intervention: 1 cup of espresso coffee/day (1C)
Number of subjects: 21
Study 34371907 — intervention group
Group type: COMPARATOR
Intervention: 3 cups of espresso coffee/day (3C)
Number of subjects: 21
Study 34371907 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 cup of espresso coffee plus two cocoa-based products containing coffee (PC) twice per day for 1 month
Number of subjects: 21
Study 32686440 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean pattern diet (diet M)
Number of subjects: 363
Study 32686440 — intervention group
Group type: COMPARATOR
Intervention: Standard hypocaloric diet (diet C)
Number of subjects: 363
Study 34373957 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronate
Number of subjects: 710
Study 34373957 — intervention group
Group type: COMPARATOR
Intervention: Denosumab
Number of subjects: 710
Study 34391875 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-1 (TRIOS 3/3Shape)
Number of subjects: 20
Study 34391875 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-2 (Virtuo Vivo/Dental Wings)
Number of subjects: 20
Study 34391875 — intervention group
Group type: COMPARATOR
Intervention: Control (Impregum/3M Espe)
Number of subjects: 20
Study 35771315 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine plus ropivacaine (25 mL of 0.3% ropivacaine + 1 μg/kg dexmedetomidine)
Number of subjects: 60
Study 35771315 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine (25 mL of 0.3% ropivacaine)
Number of subjects: 60
Study 34411199 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthwash and nose rinse with ARGOVIT® silver nanoparticles (AgNPs) solution
Number of subjects: 231
Study 34411199 — intervention group
Group type: COMPARATOR
Intervention: Conventional mouthwash and nose rinse
Number of subjects: 231
Study 35172727 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ketamine (0.5 mg/kg) + sufentanil (2 μg/kg) + tropisetron (10 mg)
Number of subjects: 275
Study 35172727 — intervention group
Group type: COMPARATOR
Intervention: Control group (sufentanil 2 μg/kg + tropisetron 10 mg)
Number of subjects: 275
Study 33340432 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g eicosapentaenoic acid (EPA) plus 1 g docosahexaenoic acid (DHA)
Number of subjects: 80
Study 33340432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 32664057 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dissolution turmeric-sesame formulation (Rhuleave-K; 1,000 mg/d)
Number of subjects: 88
Study 32664057 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen (1,000 mg/d)
Number of subjects: 88
Study 34076386 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarecycline
Number of subjects: 0
Study 32931029 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant doxorubicin, cyclophosphamide, paclitaxel, and trastuzumab (arm B, AC→T→H)
Number of subjects: 2763
Study 32931029 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant doxorubicin, cyclophosphamide, paclitaxel (arm A, AC→T)
Number of subjects: 2763
Study 32931029 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant doxorubicin, cyclophosphamide, paclitaxel, and trastuzumab (arm C, AC→T+H→H)
Number of subjects: 2763
Study 32931029 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen receptor-positive patients
Number of subjects: 2763
Study 32931029 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen receptor-negative patients
Number of subjects: 2763
Study 32931029 — intervention group
Group type: EXPERIMENTAL
Intervention: Local treatment L+RT
Number of subjects: 2763
Study 32931029 — intervention group
Group type: EXPERIMENTAL
Intervention: Local treatment M+RT
Number of subjects: 2763
Study 32931029 — intervention group
Group type: EXPERIMENTAL
Intervention: Local treatment M
Number of subjects: 2763
Study 32931029 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 to 3 positive lymph nodes L+RT
Number of subjects: 2763
Study 32931029 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 to 3 positive lymph nodes M+RT
Number of subjects: 2763
Study 32931029 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 to 3 positive lymph nodes M
Number of subjects: 2763
Study 36399712 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 mg leniolisib twice daily for 12 weeks
Number of subjects: 31
Study 34358832 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB (3 g/day)
Number of subjects: 30
Study 34358832 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 30
Study 35168957 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital home exercise (DHE)
Number of subjects: 763
Study 35168957 — intervention group
Group type: COMPARATOR
Intervention: Inactive control group
Number of subjects: 763
Study 34596103 — intervention group
Group type: EXPERIMENTAL
Intervention: Da Vinci robot‐assisted radical gastrectomy (observation group)
Number of subjects: 98
Study 34596103 — intervention group
Group type: COMPARATOR
Intervention: Open radical gastrectomy (control group)
Number of subjects: 98
Study 32729784 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g/d glutamine
Number of subjects: 66
Study 32729784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 36027560 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for subclinical cardiovascular disease
Number of subjects: 16736
Study 36027560 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 16736
Study 36027560 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for stroke
Number of subjects: 16736
Study 36027560 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for myocardial infarction
Number of subjects: 16736
Study 36027560 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for aortic dissection
Number of subjects: 16736
Study 36027560 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for aortic rupture
Number of subjects: 16736
Study 34547030 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth‐enabled hierarchical diabetes management intervention
Number of subjects: 19601
Study 34547030 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 19601
Study 34753535 — intervention group
Group type: EXPERIMENTAL
Intervention: EDS-FLU 186 µg
Number of subjects: 482
Study 34753535 — intervention group
Group type: EXPERIMENTAL
Intervention: EDS-FLU 372 µg
Number of subjects: 482
Study 34753535 — intervention group
Group type: COMPARATOR
Intervention: EDS-placebo
Number of subjects: 482
Study 34039056 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intubation
Number of subjects: 20
Study 34039056 — intervention group
Group type: COMPARATOR
Intervention: Late intubation
Number of subjects: 20
Study 34039056 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated cough occurrence
Number of subjects: 20
Study 34039056 — intervention group
Group type: EXPERIMENTAL
Intervention: Failed first attempt laryngoscopy
Number of subjects: 20
Study 34039056 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubation time
Number of subjects: 20
Study 34039056 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of failed first attempt laryngoscopy
Number of subjects: 20
Study 34039056 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate variability
Number of subjects: 20
Study 35404109 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Partial Nephrectomy (LPN)
Number of subjects: 208
Study 35404109 — intervention group
Group type: COMPARATOR
Intervention: Open Partial Nephrectomy (OPN)
Number of subjects: 208
Study 34254272 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric (NG) feeding
Number of subjects: 77
Study 34254272 — intervention group
Group type: COMPARATOR
Intervention: Nasojejunal (NJ) feeding
Number of subjects: 77
Study 32588060 — intervention group
Group type: COMPARATOR
Intervention: Provisional stenting
Number of subjects: 653
Study 32588060 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stent technique
Number of subjects: 653
Study 33432836 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care content
Number of subjects: 410
Study 33432836 — intervention group
Group type: EXPERIMENTAL
Intervention: Racial discrimination content
Number of subjects: 410
Study 33432836 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related racial discrimination stories
Number of subjects: 410
Study 33432836 — intervention group
Group type: COMPARATOR
Intervention: Non-health, nonracial discrimination stories
Number of subjects: 410
Study 33852195 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketone ester (KE) ingestion
Number of subjects: 10
Study 33852195 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric glucose (GLU) administration
Number of subjects: 10
Study 33852195 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) vehicle
Number of subjects: 10
Study 32221596 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 18244
Study 36416321 — intervention group
Group type: EXPERIMENTAL
Intervention: WaveOne
Number of subjects: 90
Study 36416321 — intervention group
Group type: EXPERIMENTAL
Intervention: 1#P drill+WaveOne
Number of subjects: 90
Study 36416321 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound P5 working end ET25+ProTaper Universal
Number of subjects: 90
Study 36416321 — intervention group
Group type: EXPERIMENTAL
Intervention: All methods
Number of subjects: 90
Study 34431398 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality (10 minutes)
Number of subjects: 88
Study 34431398 — intervention group
Group type: COMPARATOR
Intervention: Guided imagery (10 minutes)
Number of subjects: 88
Study 34431398 — intervention group
Group type: COMPARATOR
Intervention: Virtual reality vs. Guided imagery
Number of subjects: 88
Study 34431398 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 88
Study 32482361 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq (channeled videolaryngoscope)
Number of subjects: 80
Study 32482361 — intervention group
Group type: COMPARATOR
Intervention: ILMA (Intubating Laryngeal Mask Airway)
Number of subjects: 80
Study 32482361 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq
Number of subjects: 80
Study 32482361 — intervention group
Group type: COMPARATOR
Intervention: ILMA
Number of subjects: 80
Study 36156543 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional training
Number of subjects: 14
Study 36156543 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 14
Study 34597955 — intervention group
Group type: EXPERIMENTAL
Intervention: NOL-guided fentanyl administration
Number of subjects: 70
Study 34597955 — intervention group
Group type: COMPARATOR
Intervention: Standardization of care (SOC)
Number of subjects: 70
Study 34253409 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of treatments including education, orthosis, hand exercises, and topical anti-inflammatory gel
Number of subjects: 94
Study 34253409 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline function
Number of subjects: 94
Study 32434495 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 16
Study 32434495 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 16
Study 36054756 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib 45 mg/day (PACE)
Number of subjects: 350
Study 36054756 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib 45 mg/day (OPTIC)
Number of subjects: 350
Study 36054756 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib 15 mg/day (OPTIC, response-based dosing)
Number of subjects: 350
Study 36054756 — intervention group
Group type: COMPARATOR
Intervention: Serious treatment-emergent adverse events (PACE)
Number of subjects: 350
Study 36054756 — intervention group
Group type: COMPARATOR
Intervention: Serious treatment-emergent adverse events (OPTIC)
Number of subjects: 350
Study 36054756 — intervention group
Group type: COMPARATOR
Intervention: Serious treatment-emergent arterial occlusive events (PACE)
Number of subjects: 350
Study 36054756 — intervention group
Group type: COMPARATOR
Intervention: Serious treatment-emergent arterial occlusive events (OPTIC)
Number of subjects: 350
Study 33291045 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensory integration (MSI) in autistic individuals
Number of subjects: 156
Study 33291045 — intervention group
Group type: COMPARATOR
Intervention: Multisensory integration (MSI) in neurotypical individuals
Number of subjects: 156
Study 32468508 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of hyperimmune plasma from convalescent donors of COVID-19
Number of subjects: 43
Study 35696383 — intervention group
Group type: EXPERIMENTAL
Intervention: Books by Black authors
Number of subjects: 9072
Study 35696383 — intervention group
Group type: COMPARATOR
Intervention: Books by female authors
Number of subjects: 9072
Study 35696383 — intervention group
Group type: COMPARATOR
Intervention: Books by young authors
Number of subjects: 9072
Study 33090208 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of oral DMAU for 28 days
Number of subjects: 81
Study 33090208 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of oral DMAU for 28 days
Number of subjects: 81
Study 33090208 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of oral DMAU for 28 days
Number of subjects: 81
Study 33090208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 33090208 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 81
Study 35831797 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA retrograde injection (TXA-RI)
Number of subjects: 133
Study 35831797 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA-soaked absorbable Gelfoam (TXA-Gel)
Number of subjects: 133
Study 35831797 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 133